Low CD4⁺/CD25⁺/CD127⁻ regulatory T cell- and high INF-γ levels are associated with improved survival of neuroblastoma patients treated with long-term infusion of ch14.18/CHO combined with interleukin-2

Sascha Troschke-Meurer,Nikolai Siebert,Madlen Marx,Maxi Zumpe,Karoline Ehlert,Oliver Mutschlechner,Hans Loibner,Ruth Ladenstein,Holger N. Lode

Low CD4⁺/CD25⁺/CD127⁻ regulatory T cell- and high INF-γ levels are associated with improved survival of neuroblastoma patients treated with long-term infusion of ch14.18/CHO combined with interleukin-2

2019

Sascha Troschke-Meurer
Nikolai Siebert
Madlen Marx
Maxi Zumpe
Karoline Ehlert
Oliver Mutschlechner
Hans Loibner
Ruth Ladenstein
Holger N. Lode

ABSTRACTImmunotherapy with the anti-GD2 antibody (Ab) ch14.18/CHO in combination with interleukin 2 (IL-2) has improved survival of high-risk neuroblastoma (NB) patients. Here, we report immunother...

Keywords:

Antibody
Interleukin 2
Regulatory T cell
Interleukin 18
Cancer research
IL-2 receptor
Immunotherapy
Medicine
Neuroblastoma
Immunology
Interleukin-7 receptor
improved survival

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations